Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | April 03, 2023 | April 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date April 03, 2023 · Filed April 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby CLAT | 125,493 |
Reported balance
After 2023-04-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-04-03 · Gift · Disposed 259 · Balance 125,493 |
| Common StockSEC Table I · non-derivative | Direct | 312,578 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 312,578 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,963 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,963 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 23,461 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 23,461 |
| Common StockSEC Table I · non-derivative | Indirectby trust for grandch | 3,609 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,609 F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust. |
Filing footnotes · ownership attribution and instrument terms
F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2023 Filed Apr 5, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 259 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-23-000007 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by CLAT Disclosed balance after: 125,493 Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000063 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,578 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 21, 2022. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001883850-23-000050 · edgardoc.xml · derivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 42,500 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 29,005 | $750.16 | $21,758,390.80 |
DisclosureSEC source: 0001883850-23-000050 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,578 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 42,500 | $270.43 | $11,493,275.00 |
DisclosureSEC source: 0001883850-23-000050 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2023 Filed Feb 24, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 291 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000050 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 125,752 Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 22:45 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | OtherCommon Stock | 111 | $729.71 | $80,997.81 |
DisclosureSEC source: 0001883850-22-000141 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 1,961 F2 · price: Represents volume-weighted average price of sales of 111 shares of Company stock on December 20, 2022 at prices ranging from $729.44 to $729.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2022 at each separate price. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 22:45 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | OtherCommon Stock | 30 | $728.86 | $21,865.80 |
DisclosureSEC source: 0001883850-22-000141 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 2,072 F1 · price: Represents volume-weighted average price of sales of 30 shares of Company stock on December 20, 2022 at prices ranging from $728.81 to $728.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2022 at each separate price. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,254 | $0.00 Strike: $726.53 | $0.00 |
DisclosureSEC source: 0001883850-22-000139 · edgardoc.xml · derivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,254 Underlying: Common Stock · 16,254 shares Expires 2032-12-16 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,651 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000139 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,083 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 57 | $753.28 | $42,936.96 |
DisclosureSEC source: 0001883850-22-000121 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,432 Read SEC document |
| October 03, 2022 Filed Dec 13, 2022 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 304 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000121 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 126,043 Read SEC document |
| July 05, 2022 Filed Dec 13, 2022 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 357 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000121 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 126,347 Read SEC document |
| May 24, 2022 Filed Dec 13, 2022 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 23,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000121 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,489 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 06, 2022 Filed Dec 13, 2022 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 302 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000121 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 126,704 Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14,286 | $700.00 | $10,000,200.00 |
DisclosureSEC source: 0001883850-22-000031 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 23,461 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 14,286 shares of Company stock on March 30, 2022 at prices ranging from $700.00 to $700.05. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2022 at each separate price. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14,286 | $700.02 | $10,000,485.72 |
DisclosureSEC source: 0001883850-22-000031 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 127,006 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 14,286 shares of Company stock on March 30, 2022 at prices ranging from $700.00 to $700.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2022 at each separate price. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001883850-22-000020 · edgardoc.xml · derivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 48,103 | $655.29 | $31,521,414.87 |
DisclosureSEC source: 0001883850-22-000020 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,566 Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 75,000 | $179.13 | $13,434,750.00 |
DisclosureSEC source: 0001883850-22-000020 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2022 Filed Mar 15, 2022 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000020 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 141,292 Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | OtherCommon Stock | 107 | $635.03 | $67,948.21 |
DisclosureSEC source: 0001883850-21-000032 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 2,095 F1 · price: Represents volume-weighted average price of sales of 107 shares of Company stock on December 16, 2021 at prices ranging from $635.00 to $635.06. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 16, 2021 at each separate price. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | OtherCommon Stock | 19 | $634.70 | $12,059.30 |
DisclosureSEC source: 0001883850-21-000032 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 2,202 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,198 | $0.00 Strike: $644.54 | $0.00 |
DisclosureSEC source: 0001708138-21-000094 · edgardoc.xml · derivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,198 Underlying: Common Stock · 21,198 shares Expires 2031-12-08 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000094 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,669 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock. Read SEC document |
| October 04, 2021 Filed Dec 10, 2021 22:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 347 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000094 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 141,630 Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001708138-21-000066 · edgardoc.xml · derivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 49,282 | $667.39 | $32,890,313.98 |
DisclosureSEC source: 0001708138-21-000066 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,808 Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 75,000 | $179.13 | $13,434,750.00 |
DisclosureSEC source: 0001708138-21-000066 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,039 | $650.04 | $6,525,751.56 |
DisclosureSEC source: 0001708138-21-000062 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 37,747 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 10,039 shares of Company stock on August 18, 2021 at prices ranging from $650.00 to $650.31. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 18, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 19, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000062 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,090 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 02, 2021 Filed Aug 19, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 373 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000062 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 141,977 Read SEC document |
| June 14, 2021 Filed Aug 19, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000062 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,090 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 27, 2021 Filed Aug 19, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000062 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,090 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2021 Filed Aug 19, 2021 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 446 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000062 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 142,350 Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 248,079 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-21-000016 · edgardoc.xml · derivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 248,079 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,921 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-21-000016 · edgardoc.xml · derivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,921 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 137,998 | $458.48 | $63,269,323.04 |
DisclosureSEC source: 0001708138-21-000016 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,090 Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 248,079 | $52.03 | $12,907,550.37 |
DisclosureSEC source: 0001708138-21-000016 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,921 | $52.03 | $99,949.63 |
DisclosureSEC source: 0001708138-21-000016 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Feb 24, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 414 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000016 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 142,796 Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,680 | $0.00 Strike: $492.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000116 · edgardoc.xml · derivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,680 Underlying: Common Stock · 27,680 shares Expires 2030-12-09 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000116 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,088 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock. Read SEC document |
| November 19, 2020 Filed Dec 11, 2020 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000116 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by trust for grandch Disclosed balance after: 3,609 F2 · ownership.nature: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust. Read SEC document |
| November 19, 2020 Filed Dec 11, 2020 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000116 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 47,786 Read SEC document |
| October 06, 2020 Filed Dec 11, 2020 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 349 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000116 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 143,210 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 998 | $607.43 | $606,215.14 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 15 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 50,192 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 998 shares of Company stock on August 11, 2020 at prices ranging from $607.26 to $607.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,684 | $606.51 | $1,627,872.84 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 14 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 51,190 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 2,684 shares of Company stock on August 11, 2020 at prices ranging from $606.19 to $606.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,331 | $605.41 | $2,016,620.71 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 13 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 53,874 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 3,331 shares of Company stock on August 11, 2020 at prices ranging from $605.00 to $605.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,171 | $604.35 | $1,916,393.85 |
DisclosureSEC source: 0001708138-20-000094 · edgardoc.xml · nonDerivative · entry 12 VAGELOS P ROY · CIK 0001013064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 57,205 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 3,171 shares of Company stock on August 11, 2020 at prices ranging from $604.01 to $604.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.